issued
on 01 Oct 2024
Last Applicant/ Owned by
Route 206 & Province Line Road
Princeton
NJ
08543
Serial Number
98229386 filed on 18th Oct 2023
Registration Number
N/A
Correspondent Address
Xiomara Triana
Xiomara Triana BRISTOL-MYERS SQUIBB COMPANY
TRADEMARK DEPT., MAILSTOP D.4243
PRINCETON, NJ 08648-4000
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.
N/A
N/A
No 98229386
No Service/Collective Mark
No 00162819-US
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
01st Oct 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
06th Aug 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
06th Aug 2024 | PUBLISHED FOR OPPOSITION |
17th Jul 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
29th Jun 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
26th Jun 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
26th Jun 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
26th Jun 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
11th Jun 2024 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
11th Jun 2024 | PRIORITY ACTION E-MAILED |